DeepSeek triggers shock waves for AI giants, but the disruption won’t last
John Belton, a portfolio manager at Gabelli Funds, an asset management firm whose funds include shares of Nvidia, Microsoft, Amazon, and others, said DeepSeek’s achievements are real, but some of the company’s claims are misleading.
Nvidia faces a reckoning as Chinese upstart raises questions about Wall Street’s darling
“As for Nvidia itself, this isn’t the first time a major tech stock has faced existential questions,” said John Belton, portfolio manager at Gabelli Funds. “We’ve seen similar situations with Microsoft, Apple, Meta, Google, Amazon, and Netflix — companies that were once doubted but ultimately rebounded.”
CNBC Daily Open: DeepSeek batters Nvidia but reinforces AI trend
Shares of Salesforce, Adobe and Palo Alto Networks rose on the prospect that AI costs could go down and expand their margins, according to John Belton, portfolio manager at Gabelli Funds.
Boeing may soon sell some of its businesses. That could finally boost the stock.
“The moat is, of course, their commercial airplanes and defense businesses,” with its commercial jet-making unit a “stalwart in the industry,” said Tony Bancroft, a portfolio manager with Gabelli Funds. Wall Street would view a “leaner” Boeing very favorably.
Panic selling on DeepSeek news crunches Nasdaq, but insiders say frightenly ”excellent advancement” is being misread — and it”s hardly new news
The market took a long time to awaken to the threat, but ‘this news is not brand new
Billionaire Mario Gabelli’s Top 15 Stock Picks
In this article, we discuss the top 15 stock picks of billionaire Mario Gabelli.
Most of the bad news is behind Boeing’ after Q4 losses
Gabelli Funds portfolio manager Tony Bancroft joins Julie Hyman and Josh Lipton on Market Domination to discuss his outlook for the struggling aerospace titan.
Elevance eases investor concerns with better-than-feared quarterly profit
The results are definitely better than feared … hopefully this means that we are starting to see a turnaround in the Medicaid business following the recent re-eligibility checks
Elevance Health earnings boost health-insurance stocks after upbeat outlook
“The results are definitely better than feared,” said Daniel Barasa, portfolio manager at Gabelli Funds. “Hopefully this means that we are starting to see a turnaround in the Medicaid business following the recent re-eligibility checks.”
J&J beats quarterly sales and profit estimates on cancer drug sales
The currency impact was a ‘negative surprise’” in an otherwise routine quarterly report
J&J Skids After Dow Giant Beat Earnings Views, But ”Prudent” Guidance Disappoints
Jeff Jonas, portfolio manager at Gabelli Funds, called out depression drug Spravato. Spravato sales rose 44% year over year to $297 million and narrowly topped forecasts.
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Jeff Jonas, a portfolio manager at Gabelli Funds, said that analysts may not have fully modeled for foreign-exchange headwinds, so the guidance was “a bit of a negative surprise.”